Table 1.
Comparison of laboratory parameters prior to bariatric surgery and thereafter at the onset time of liver function deterioration
| Study population, n = 10 | Before bariatric surgery | Peak of liver dysfunction |
|---|---|---|
| Female sex, % (n) | 80 (8/10) | 80 (8/10) |
| Age in years, median (range) | 40 (21–66) | 48 (22–66) |
| BMI (kg/m2), median (range) | 49.2 (38–64) | 22.2 (20.8–30.5) |
| NAFLD | ||
| Liver disease, % (n) | 60 (6/10) | 100 (10/10) |
| Steatosis/fibrosis, % (n) | 50 (5/10) | 70 (7/10) |
| Cirrhosis, % (n) | 10 (1/10) | 30 (3/10) |
| No liver disease | 30 (3/10) | 0 (0/10) |
| Missing, % (n) | 10 (1/10) | 0 (0/10) |
| Liver enzymes | ||
| AST (U/L), median (range) | 25 (14.5–57) | 32.5 (14–258) |
| ALT (U/L), median (range) | 38 (12.5–127) | 26 (11–230) |
| GGT (U/L), median (range) | 33 (12–110) | 38.5 (11–468) |
| Hypercholesterolemia, % (n) | 20 (2) | 0 (0) |
| Cholesterol (mg/dl), median (range) | 175.3 (109.5–228) | 98.5 (66–146) |
| HDL (mg/dl), median (range) | 52.5 (42–59) | 42 (4–54) |
| LDL (mg/dl), median (range) | 111.2 (92.1–152.8) | 37.2 (11.2–92.2) |
| Hypertriglyceridemia, % (n) | 20 (2) | 10 (1) |
| Triglycerides (mg/dl), median (range) | 92 (46–152) | 50.5 (28–249) |
| T2DM, % (n) | 10 (1) | 0 (0) |
| OAD, % (n) | 10 (1) | 0 (0) |
| Insulin, % (n) | 0 (0) | 0 (0) |
| HbA1c (%), median (range) | 5.2 (4.7–5.7) | 3.9 (3.7–4) |
| aHTN, % (n) | 40% (4) | 10 (1) |
| Hyperuricemia, % (n) | 20% (2) | 0 (0) |
| Obstructive sleep apnea, % (n) | 0 (0) | 0 (0) |
| CAD, % (n) | 0 (0) | 0 (0) |
| Congestive heart failure, % (n) | 10 (1) | 10 (1) |
| PH, % (n) | 10 (1) | 10 (1) |
BMI body mass index, NAFLD nonalcoholic fatty liver disease, AST alanin-aminotransferase, GGT gamma-glutamyl-transferase, HDL high-density lipoproteins, LDL low-density lipoprotein, T2DM type 2 diabetes mellitus, OAD oral antidiabetics, aHTN arterial hyptertension, CAD coronary artery disease, PH pulmonary hypertension